Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome

Virchows Archiv

Volumn 450, Issue 3, 2007, Pages 279-285

  Surowiak, Paweł ^a,b,c   Materna, Verena ^a   Maciejczyk, Adam ^c   Pudełko, Marek ^c   Markwitz, Ewa ^d   Spaczyński, Marek ^d   Dietel, Manfred ^a   Zabel, MacIej ^b,d   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cisplatin resistance; Metallothionein; Nuclear expression; Ovarian cancer

Indexed keywords

CISPLATIN; DNA; METALLOTHIONEIN; PLATINUM;

ARTICLE; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; METALLOTHIONEIN; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 33847722674     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0362-7     Document Type: Article

References (16)

1. Apostolova MD, Chen S, Chakrabarti S, Cherian MG (2001) High-glucose-induced metallothionein expression in endothelial cells: An endothelin-mediated mechanism. Am J Physiol Cell Physiol 281:C899-C907
2. Apostolova MD, Cherian MG (2000) Delay of M-phase onset by aphidicolin can retain the nuclear localization of zinc and metallothionein in 3T3-L1 fibroblasts. J Cell Physiol 183:247-253
3. Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Karnel LH, Winchester DPSO (1993) National survey of ovarian carcinoma. 1. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629-1638
4. Cherian MG, Apostolova MD (2000) Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 46:347-356
5. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, Lage H (2006) Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines. Int J Cancer 118:1699-1712
6. Hagrman D, Goodisman J, Dabrowiak JC, Souid AK (2003) Kinetic study on the relation of cisplatin with metallothionein. Drug Metab Dispos 31:916-923
7. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Sem Surg Oncol 19:3-10
8. Kondo Y, Kuo SM, Watkins SC, Lazo JS (1995) Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55:474-477
9. Kowalski P, Surowiak P, Lage H (2005) Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Molec Ther 11:508-522
10. Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22:188-199
11. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138-140
12. Siegsmund MJ, Marx C, Seeman O, Schummer B, Steidler A, Toktomambetova L, Kohrmann KU, Rassweiler J, Alken P (1999) Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 27:157-163
13. Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF (1998) The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559-565
14. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M (2005) Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv 447:626-633
15. Takahashi Y, Ogra Y, Suzuki KT (2005) Nuclear trafficking of metallothionein requires oxidation of a cytosolic partner. J Cell Physiol 202:563-569
16. Wrigley E, Verpaget HW, Jayson GC, McGown AT (2000) Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 126:717-721